Perceptive Pharma Research | Victoria Gastroenterology logo

Perceptive Pharma Research | Victoria Gastroenterology

Research site
106 Springwood Drive, Suite 100, Victoria, Texas, United States of America
Site insights

Top conditions

Ulcer (6 trials)

Colitis (6 trials)

Ulcerative Colitis (6 trials)

Crohn Disease (4 trials)

Non-alcoholic Fatty Liver Disease (1 trial)

Top treatments


Parent organization

This site is a part of Perceptive Pharma Research

Data sourced from

Contact this site

Site Coordinator

Verified by this site


7 of 12
Status: Active
Trial type: Interventional
Funder type: Industry

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Crohn's Disease
Drug: Etrasimod
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 1

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participant...

Active, not recruiting
Celiac Disease
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Drug: TAK-062 Placebo

The study consists of 4 sub-studies, as follows:Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety...

Active, not recruiting
Crohn's Disease
Drug: Risankizumab SC
Drug: Risankizumab On-Body Injector (OBI)

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: risankizumab
Drug: placebo for risankizumab

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Ulcerative Colitis
Drug: Etrasimod

Trial sponsors

AbbVie logo

AbbVie (2 trials)


Arena Pharmaceuticals (2 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems